BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

70.73 -0.09 (-0.13%)

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

May 12, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

May 07, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk ↗

May 02, 2025

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility.

Via Benzinga

Topics World Trade

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

A Look Ahead: BridgeBio Pharma's Earnings Forecast ↗

April 28, 2025

Via Benzinga

Prediction: BridgeBio Pharma Will Beat the Market. Here's Why ↗

March 03, 2025

Via The Motley Fool

BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations ↗

April 29, 2025

The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market.

Via Investor's Business Daily

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

April 29, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

April 28, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

April 22, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 11, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

March 31, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Competitive Analysis In The ATTR-CM Field ↗

March 30, 2025

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the...

Via Talk Markets

Topics Stocks / Equities

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug ↗

March 27, 2025

BridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it.

Via Benzinga

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

March 27, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

March 24, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 21, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio ↗

March 21, 2025

Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio.

Via Investor's Business Daily

BridgeBio Announces CFO Succession

March 17, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

February 27, 2025

Via Benzinga

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

February 26, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

February 24, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

February 20, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

February 13, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

February 11, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Top 4 Health Care Stocks You May Want To Dump In Q1 ↗

January 21, 2025

Via Benzinga

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Via Investor's Business Daily

Topics Economy

BridgeBio Pharma Stock Earns 87 RS Rating ↗

January 14, 2025

BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.

Via Investor's Business Daily

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. ↗

January 13, 2025

Some companies saw their shares skyrocket on preliminary reports, but others took hits.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.